

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 731063150 US  
Express Mail Label Number

June 19, 2006  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
KUDARAVALLI ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP04/001692

FILED: 20 FEBRUARY 2004

U.S. APPLICATION NO: 10/545,695

35 USC §371 DATE: 16 AUGUST 2005

FOR: METHODS FOR THE PREDICTION OF SUICIDALITY DURING  
TREATMENT

**MS: PCT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. The listed references were cited in the International Search Report. Since these references are of record in the instant PCT application PCT/EP04/001692, copies are not enclosed herewith. A copy of the International Search Report and the Written Opinion are enclosed with this Response.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3346

  
\_\_\_\_\_  
John T. Prince  
Attorney for Applicants  
Reg. No. 43,019

Date: June 19, 2006

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-32889A  
APPLICATION NO.  
10/545,695  
APPLICANT  
KUDARAVALLI ET AL.  
FILING DATE  
AUGUST 16, 2005

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AC						<input type="checkbox"/>	<input type="checkbox"/>
	AD						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AE	Badri, et al., "Dopamine and serotonin system genes may predict clinical response to clozapine", <i>Am. J. of Human Gen.</i> , Vol. 59 (1996)
AF	Basile et al., "Pharmacogenomics in schizophrenia: the quest for individualized therapy", <i>Human Molecular Genetics</i> , Vol. 11, No. 20, pp. 2517-2530, (2002)
AG	Donovan et al., "Human and mouse dopamine transporter genes: Conservation of 5'-flanking sequence elements and gene structures", <i>Molecular Brain Research</i> , Vol. 30, No. 2, pp. 327-335, (1995)
AH	Gonzales et al., "Synonymous-non-synonymous mutation rates between sequences containing ambiguous nucleotides (Syn-SCAN)", <i>Bioinformatics</i> , Vol. 18, No. 6, pp. 886-887, (June 2002)
AI	Greenwood, et al., "Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder", <i>Am. J. of Med. Gen.</i> , Vol. 105 (2001)
AJ	Meltzer, et al., "Clozapine treatment for suicidality in schizophrenia: International suicide prevention trial (Intersept)", <i>Archives of Gen. Psych.</i> , Vol. 60 (2003)
AK	GenBank Accession No. AF119117.1

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.